Cargando…
Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
BACKGROUND AND AIMS: The effect of antidepressant therapy on Inflammatory Bowel Disease (IBD) remains controversial. This trial aimed to assess whether adding venlafaxine to standard therapy for IBD improved the quality of life (QoL), mental health, and disease activity of patients with IBD with anx...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160994/ https://www.ncbi.nlm.nih.gov/pubmed/35664492 http://dx.doi.org/10.3389/fpsyt.2022.880058 |
_version_ | 1784719390435966976 |
---|---|
author | Liang, Chang Chen, Pingrun Tang, Yu Zhang, Chuheng Lei, Na Luo, Ying Duan, Shihao Zhang, Yan |
author_facet | Liang, Chang Chen, Pingrun Tang, Yu Zhang, Chuheng Lei, Na Luo, Ying Duan, Shihao Zhang, Yan |
author_sort | Liang, Chang |
collection | PubMed |
description | BACKGROUND AND AIMS: The effect of antidepressant therapy on Inflammatory Bowel Disease (IBD) remains controversial. This trial aimed to assess whether adding venlafaxine to standard therapy for IBD improved the quality of life (QoL), mental health, and disease activity of patients with IBD with anxious and depressive symptoms. METHODS: A prospective, randomized, double-blind, and placebo-controlled clinical trial was conducted. Participants diagnosed with IBD with symptoms of anxiety or depression were randomly assigned to receive either venlafaxine 150 mg daily or equivalent placebo and followed for 6 months. Inflammatory Bowel Disease Questionnaire (IBDQ), Mayo score, Crohn's disease activity index (CDAI), Hospital Anxiety and Depression Scale (HADS), and blood examination were completed before the enrollment, during, and after the follow-up. Mixed linear models and univariate analyses were used to compare groups. RESULTS: Forty-five patients with IBD were included, of whom 25 were randomized to receive venlafaxine. The mean age was 40.00 (SD = 13.12) years old and 25 (55.6%) were male. Venlafaxine showed a significant improvement on QoL (p < 0.001) and disease course (p = 0.035), a greater reduction in HADS (anxiety: p < 0.001, depression: p < 0.001), Mayo scores (p < 0.001), and CDAI (p = 0.006) after 6 months. Venlafaxine had no effect on IL-10 expression, endoscopic scores, relapse rate, and use rate of biologics and corticosteroids, but did reduce serum level of erythrocyte estimation rate (ESR; p = 0.003), C-reactive protein (CRP; p < 0.001) and tumor necrosis factor-α (TNF-α; p = 0.009). CONCLUSIONS: Venlafaxine has a significantly beneficial effect on QoL, IBD activity, and mental health in patients with IBD with comorbid anxious or depressive symptoms. (Chinese Clinical Trial Registry, ID: ChiCTR1900021496). |
format | Online Article Text |
id | pubmed-9160994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91609942022-06-03 Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial Liang, Chang Chen, Pingrun Tang, Yu Zhang, Chuheng Lei, Na Luo, Ying Duan, Shihao Zhang, Yan Front Psychiatry Psychiatry BACKGROUND AND AIMS: The effect of antidepressant therapy on Inflammatory Bowel Disease (IBD) remains controversial. This trial aimed to assess whether adding venlafaxine to standard therapy for IBD improved the quality of life (QoL), mental health, and disease activity of patients with IBD with anxious and depressive symptoms. METHODS: A prospective, randomized, double-blind, and placebo-controlled clinical trial was conducted. Participants diagnosed with IBD with symptoms of anxiety or depression were randomly assigned to receive either venlafaxine 150 mg daily or equivalent placebo and followed for 6 months. Inflammatory Bowel Disease Questionnaire (IBDQ), Mayo score, Crohn's disease activity index (CDAI), Hospital Anxiety and Depression Scale (HADS), and blood examination were completed before the enrollment, during, and after the follow-up. Mixed linear models and univariate analyses were used to compare groups. RESULTS: Forty-five patients with IBD were included, of whom 25 were randomized to receive venlafaxine. The mean age was 40.00 (SD = 13.12) years old and 25 (55.6%) were male. Venlafaxine showed a significant improvement on QoL (p < 0.001) and disease course (p = 0.035), a greater reduction in HADS (anxiety: p < 0.001, depression: p < 0.001), Mayo scores (p < 0.001), and CDAI (p = 0.006) after 6 months. Venlafaxine had no effect on IL-10 expression, endoscopic scores, relapse rate, and use rate of biologics and corticosteroids, but did reduce serum level of erythrocyte estimation rate (ESR; p = 0.003), C-reactive protein (CRP; p < 0.001) and tumor necrosis factor-α (TNF-α; p = 0.009). CONCLUSIONS: Venlafaxine has a significantly beneficial effect on QoL, IBD activity, and mental health in patients with IBD with comorbid anxious or depressive symptoms. (Chinese Clinical Trial Registry, ID: ChiCTR1900021496). Frontiers Media S.A. 2022-05-19 /pmc/articles/PMC9160994/ /pubmed/35664492 http://dx.doi.org/10.3389/fpsyt.2022.880058 Text en Copyright © 2022 Liang, Chen, Tang, Zhang, Lei, Luo, Duan and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Liang, Chang Chen, Pingrun Tang, Yu Zhang, Chuheng Lei, Na Luo, Ying Duan, Shihao Zhang, Yan Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial |
title | Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial |
title_full | Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial |
title_fullStr | Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial |
title_full_unstemmed | Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial |
title_short | Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial |
title_sort | venlafaxine as an adjuvant therapy for inflammatory bowel disease patients with anxious and depressive symptoms: a randomized controlled trial |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160994/ https://www.ncbi.nlm.nih.gov/pubmed/35664492 http://dx.doi.org/10.3389/fpsyt.2022.880058 |
work_keys_str_mv | AT liangchang venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT chenpingrun venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT tangyu venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT zhangchuheng venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT leina venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT luoying venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT duanshihao venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial AT zhangyan venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial |